The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603.
Liza Cosca Villaruz
No relevant relationships to disclose
Grace Huang
No relevant relationships to disclose
Marjorie Romkes
No relevant relationships to disclose
John M. Kirkwood
No relevant relationships to disclose
Shama C. Buch
No relevant relationships to disclose
Tomoko Nukui
No relevant relationships to disclose
Keith Flaherty
No relevant relationships to disclose
Sandra J. Lee
No relevant relationships to disclose
Adrian Lee
No relevant relationships to disclose
Kusum Pandit
No relevant relationships to disclose
Irina Abecassis
No relevant relationships to disclose
Katherine L. Nathanson
No relevant relationships to disclose
Panayiotis V Benos
No relevant relationships to disclose
Hussein Abdul-Hassan Tawbi
No relevant relationships to disclose